# Study of Bexarotene in Patients With Acute Myeloid Leukemia

> **NCT00316030** · PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 54 (—)

## Conditions studied

- AML
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Bexarotene

## Key facts

- **NCT ID:** NCT00316030
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 54 (—)
- **Last updated:** 2016-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00316030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00316030, "Study of Bexarotene in Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00316030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*